Dzutsev Amiran H, Belyakov Igor M, Isakov Dmitry V, Margulies David H, Berzofsky Jay A
Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1578, USA.
Int Immunol. 2007 Apr;19(4):497-507. doi: 10.1093/intimm/dxm016. Epub 2007 Mar 21.
In the course of viral infection, the immune system exploits only a fraction of the available CTL repertoire and focuses on a few of a myriad of potentially antigenic peptides. This phenomenon, known as immunodominance, depends on a number of factors, including antigen processing and transport, MHC binding, competition for antigen-presenting cells, availability of the CD8 T cell repertoire and other mechanisms that function largely by restricting the immune response. Here we elucidate a novel mechanism that increases the immunodominance of the epitope rather by enhancing the immune response. Using a peptide-specific MHC-restricted mAb and functional assays of CTL activation, we show that T cells with high avidity for the immunodominant, H-2D(d) restricted, P18-I10 epitope expand rapidly following immunization, and this expansion in turn determines the level of the P18-I10 epitope immunodominance. This proliferation has little dependence on the number of MHC-peptide complexes. Since most self-reactive T cells of high avidity are depleted in the thymus, the selection of immunodominant epitopes based on the expansion of high-avidity T cells in the periphery reduces the potential for autoimmunity.
在病毒感染过程中,免疫系统仅利用了一小部分可用的细胞毒性T淋巴细胞(CTL)库,并聚焦于无数潜在抗原肽中的少数几种。这种现象被称为免疫显性,它取决于多种因素,包括抗原加工与转运、主要组织相容性复合体(MHC)结合、对抗抗原呈递细胞的竞争、CD8 T细胞库的可用性以及其他主要通过限制免疫反应起作用的机制。在此,我们阐明了一种通过增强免疫反应来提高表位免疫显性的新机制。利用一种肽特异性的MHC限制性单克隆抗体以及CTL激活的功能分析,我们发现对免疫显性的、H-2D(d)限制性的P18-I10表位具有高亲和力的T细胞在免疫后迅速扩增,而这种扩增反过来又决定了P18-I10表位的免疫显性水平。这种增殖对MHC-肽复合物的数量依赖性很小。由于大多数具有高亲和力的自身反应性T细胞在胸腺中被清除,基于外周高亲和力T细胞扩增来选择免疫显性表位可降低自身免疫的可能性。
Int Immunol. 2007-4
Biochem Biophys Res Commun. 2004-4-2
AIDS Res Hum Retroviruses. 2001-6-10
Front Immunol. 2015-11-18
Adv Cancer Res. 2014
Adv Cancer Res. 2013
PLoS Pathog. 2013-4-25
J Natl Cancer Inst. 2012-3-6
Immunol Cell Biol. 2011-5-17